August 12, 2021
August 12, 2021 – Cipla has received final approval from the U.S. FDA for its generic version of Durezol® (difluprednate ophthalmic emulsion – Novartis) 0.5%.
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health
August 12, 2021
August 12, 2021 – The U.S. FDA has modified the emergency use authorization (EUA) for both the Pfizer
August 10, 2021
August 10, 2021 – SterRx, LLC, has recalled three lots of Sodium Bicarbonate in 5% Dextrose Injection 150mEq per 1,000mL to the hospital pharmacy level as a result of waterborne
August 6, 2021
August 6, 2021 – The U.S. FDA has approved Sanofi’s Nexviazyme® (avalglucosidase alfa-ngpt), to treat
late-onset Pompe disease (LOPD) in patients who are at least a year old.
August 6, 2021
August 6, 2021 – KVK Tech, Inc., has voluntarily recalled two lots of Atovaquone Oral Suspension, USP 750
mg/5mL, following customer complaints that the product was unusually gritty
August 2, 2021
August 2, 2021 – The U.S. FDA has approved SaphneloTM (anifrolumab-fnia), manufactured by AstraZeneca,
to treat moderate to severe systemic lupus erythematosus (SLE) in adults who
July 30, 2021
July 29, 2021
July 29, 2021 – The U.S. FDA has approved changes to the Risk Evaluation and Mitigation Strategy (REMS)
program